Global Cybersecurity Forum (GCF) to Convene Global Leaders In-Person in February 2022
28.9.2021 15:47:00 EEST | Business Wire | Press release
The 2022 edition of the Global Cybersecurity Forum (GCF) will be held on 1st and 2nd of February 2022 in Riyadh under the High Patronage of the Custodian of the Two Holy Mosques King Salman bin Abdulaziz Al Saud.
The GCF 2022 theme, Rethinking the Global Cyber Order , will focus on the root challenges in cybersecurity and explore how the global cyber community can seize upon the many benefits cyberspace offers to humanity. Building off the momentum from its previous forums, the GCF will continue to grow into an action-oriented global platform that integrates the global cybersecurity community. Through its annual events, continuous research, design and launch of new initiatives, and more, the GCF aims to catalyze socioeconomic change, push the knowledge boundaries on core cybersecurity topics, foster investment and build the foundations for global cooperation in cyberspace.
Interactive and dynamic discussions and sessions will engage prominent speakers and participants representing high-level policy makers, industry leaders, experts from NGOs, international organizations, and academia driving the conversation from a range of perspectives and experiences and cover a range of sub-themes that include:
- The evolving international order in cyberspace;
- The current and future state of cybersecurity threats;
- Technologies of the future as solutions to threats;
- The human dimensions of cybersecurity in the future of work;
- Leveraging market forces and economic incentives
- Bridging global cyber divides and strengthening human-centric cybersecurity
The GCF, hosted by the National Cybersecurity Authority (NCA), was launched in February 2020, during the Kingdom of Saudi Arabia’s G20 Presidency, as a global platform aiming to build a more resilient and better cyberspace for all. The platform emphasizes the importance of international collaboration among diverse stakeholders and nations to accomplish this goal. In line with these objectives, GCF has convened former Heads of States, industry leaders, policymakers, senior representatives from International Organizations, prominent academics and thought leaders from across the globe, and executives from the finance, health, energy, and transport sectors.
When COVID struck, the GCF hosted its first Virtual Dialogue entitled “Cyberspace: What Now, What Next?”, attracting over 250,000 individuals from more than 100 countries. The multi-disciplinary sessions highlighted a series of key themes for the global cybersecurity community, including economic incentives, the talent gap, investment, trust, cyber diplomacy, integrated awareness, and cyber conflict readiness.
The GCF team welcomes global participation in the coming event and looks forward to expanding dialogue and driving action together to create a better cyberspace for all.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005711/en/
Contact information
Alaa Al Faadhel
afaadhel@globalcybersecurityforum.com
https://globalcybersecurityforum.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom